↓ Skip to main content

Latest clinical recommendations on valproate use for migraine prophylaxis in women of childbearing age: overview from European Medicines Agency and European Headache Federation

Overview of attention for article published in The Journal of Headache and Pain, August 2018
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (92nd percentile)
  • High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

news
2 news outlets
blogs
1 blog
twitter
17 X users

Citations

dimensions_citation
18 Dimensions

Readers on

mendeley
47 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Latest clinical recommendations on valproate use for migraine prophylaxis in women of childbearing age: overview from European Medicines Agency and European Headache Federation
Published in
The Journal of Headache and Pain, August 2018
DOI 10.1186/s10194-018-0898-3
Pubmed ID
Authors

Efstratia Vatzaki, Sabine Straus, Jean-Michel Dogne, Juan Garcia Burgos, Thomas Girard, Paolo Martelletti

Abstract

Migraine is a common and burdensome neurological condition which affects mainly female patients during their childbearing years. Valproate has been widely used for the prophylaxis of migraine attacks and is also included in the main European Guidelines. Previous (2014) European recommendations on limiting the use of valproate in women of childbearing age did not achieve their objective in terms of limiting the use of valproate in women of childbearing age and raising awareness regarding the hazardous effect of valproate to children exposed in utero. The teratogenic and foetotoxic effects of valproate are well documented, and more recent studies show that there is an even greater neurodevelopmental risk to children exposed to valproate in the womb. The latest 2018 European review from the European Medicines Agency, with the active participation of the European Headache Federation, concluded that not enough has been done to mitigate the risks associated with in utero exposure to valproate. The review called for more extensive restrictions to the conditions for prescribing, better public awareness, and a more effective education campaign in migrainous women.

X Demographics

X Demographics

The data shown below were collected from the profiles of 17 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 47 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 47 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 7 15%
Student > Master 6 13%
Student > Bachelor 5 11%
Other 5 11%
Student > Doctoral Student 4 9%
Other 8 17%
Unknown 12 26%
Readers by discipline Count As %
Medicine and Dentistry 17 36%
Nursing and Health Professions 6 13%
Pharmacology, Toxicology and Pharmaceutical Science 5 11%
Unspecified 1 2%
Biochemistry, Genetics and Molecular Biology 1 2%
Other 2 4%
Unknown 15 32%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 31. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 September 2022.
All research outputs
#1,242,294
of 25,182,110 outputs
Outputs from The Journal of Headache and Pain
#139
of 1,514 outputs
Outputs of similar age
#25,813
of 336,960 outputs
Outputs of similar age from The Journal of Headache and Pain
#6
of 43 outputs
Altmetric has tracked 25,182,110 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,514 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 19.4. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 336,960 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 43 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.